Labcorp Holdings Inc. (LH)
Labcorp Holdings Inc. (LH) Short-Term Debt
The short-term debt for Labcorp Holdings Inc. (LH) is $695.80 Million with a year-over-year change of -30.44%. Short-term debt includes all borrowings and debt obligations due within one year, including the current portion of long-term debt, commercial paper, and credit facilities.
LH Short-Term Debt Chart
LH Short-Term Debt
$695.80M+27.76% 20Y
Zoom
Current Short-Term Debt
$695.80M
$695.80 Million
Year-over-Year Change
-30.44%
vs. $1.00B prior year
Historical Data
30
Years of data available
Annual Short-Term Debt History
| Year | Short-Term Debt | YoY Change | % Change |
|---|---|---|---|
| 2025 | $695.80M | $-304.50M | -30.44% |
| 2024 | $1.00B | +$500,000 | +0.05% |
| 2023 | $999.80M | +$698.50M | +231.83% |
| 2022 | $301.30M | +$299.80M | +19986.67% |
| 2021 | $1.50M | $-375.20M | -99.60% |
| 2020 | $376.70M | $-38.50M | -9.27% |
| 2019 | $415.20M | +$405.20M | +4052.00% |
| 2018 | $10.00M | $-399.20M | -97.56% |
| 2017 | $409.20M | $-131.90M | -24.38% |
| 2016 | $541.10M | +$122.60M | +29.30% |
| 2015 | $418.50M | +$74.60M | +21.69% |
| 2014 | $343.90M | +$233.10M | +210.38% |
| 2013 | $110.80M | $-369.20M | -76.92% |
| 2012 | $480.00M | +$344.50M | +254.24% |
| 2011 | $135.50M | $-226.20M | -62.54% |
| 2010 | $361.70M | $-55.50M | -13.30% |
| 2009 | $417.20M | +$296.40M | +245.36% |
| 2008 | $120.80M | $-468.70M | -79.51% |
| 2007 | $589.50M | +$35.10M | +6.33% |
| 2006 | $554.40M | +$9.80M | +1.80% |
| 2005 | $544.60M | +$544.50M | +544500.00% |
| 2004 | $100,000 | $-523.40M | -99.98% |
| 2003 | $523.50M | +$523.10M | +130775.00% |
| 2002 | $400,000 | +$400,000 | — |
| 2001 | $0 | $-132.00M | -100.00% |
| 2000 | $132.00M | +$37.00M | +38.95% |
| 1999 | $95.00M | +$22.50M | +31.03% |
| 1998 | $72.50M | +$72.50M | — |
| 1997 | $0 | $-18.70M | -100.00% |
| 1996 | $18.70M | — | — |
Data as of Sunday, June 14, 2026
About Labcorp Holdings Inc.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Adam H. Schechter